[Psychedelics for existential distress in terminally ill patients]

Area of Science:

• Psychiatry
• Psychopharmacology
• Palliative Care

Background:

• Existential distress, anxiety, and depression are common in terminally ill patients.
• Psychotherapeutic interventions offer temporary relief, with no established pharmacological treatments.
• Addressing existential distress is crucial for improving end-of-life care.

Purpose of the Study:

• To review existing literature on psychedelic treatment for existential distress in terminally ill patients.
• To synthesize findings from early and recent clinical studies.
• To identify gaps and future directions in psychedelic research for palliative care.

Main Methods:

• Conducted a literature search in PubMed/Medline databases.
• Included studies on classic psychedelics and ketamine.
• Supplemented findings with cross-references from relevant literature.

Main Results:

• 14 clinical studies were identified (6 pre-1980, 8 post-2000).
• Early studies showed promise but had methodological limitations.
• Recent studies with LSD, psilocybin, and ketamine indicate positive effects on well-being, quality of life, and reduced anxiety/depression.
• Mystical experiences correlated with positive outcomes; few adverse effects reported.

Conclusions:

• Psychedelic treatment (classic psychedelics, ketamine) appears promising for existential distress in terminally ill patients.
• Current evidence is limited by study design and generalizability.
• Larger, methodologically rigorous clinical trials in diverse populations are necessary.